BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19560747)

  • 1. Biology and treatment of primary central nervous system lymphoma.
    Algazi AP; Kadoch C; Rubenstein JL
    Neurotherapeutics; 2009 Jul; 6(3):587-97. PubMed ID: 19560747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Central Nervous System Lymphoma.
    Löw S; Batchelor TT
    Semin Neurol; 2018 Feb; 38(1):86-94. PubMed ID: 29548055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary central nervous system lymphoma.
    Stern JI; Raizer JJ
    Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S63-70. PubMed ID: 16274272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis and management of primary CNS lymphoma.
    Roth P; Korfel A; Martus P; Weller M
    Expert Rev Anticancer Ther; 2012 May; 12(5):623-33. PubMed ID: 22594897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry.
    Krogh-Jensen M; D'Amore F; Jensen MK; Christensen BE; Thorling K; Pedersen M; Johansen P; Boesen AM; Andersen E
    Leuk Lymphoma; 1995 Oct; 19(3-4):223-33. PubMed ID: 8535213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and management of primary central nervous system lymphoma.
    Han CH; Batchelor TT
    Cancer; 2017 Nov; 123(22):4314-4324. PubMed ID: 28950405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances and challenges in the treatment of primary central nervous system lymphoma.
    Yang H; Xun Y; Yang A; Liu F; You H
    J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
    Chen T; Liu Y; Wang Y; Chang Q; Wu J; Wang Z; Geng D; Yu JT; Li Y; Li XQ; Chen H; Zhuang D; Li J; Wang B; Jiang T; Lyu L; Song Y; Qiu X; Li W; Lin S; Zhang X; Lu D; Lei J; Chen Y; Mao Y
    J Hematol Oncol; 2022 Sep; 15(1):136. PubMed ID: 36176002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the therapy of primary central nervous system lymphoma.
    Plotkin SR; Batchelor TT
    Clin Lymphoma; 2001 Mar; 1(4):263-75; discussion 276-7. PubMed ID: 11707839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
    de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
    Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary central nervous system lymphoma.
    Löw S; Han CH; Batchelor TT
    Ther Adv Neurol Disord; 2018; 11():1756286418793562. PubMed ID: 30305848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and opportunities in primary CNS lymphoma: A systematic review.
    Kerbauy MN; Moraes FY; Lok BH; Ma J; Kerbauy LN; Spratt DE; Santos FP; Perini GF; Berlin A; Chung C; Hamerschlak N; Yahalom J
    Radiother Oncol; 2017 Mar; 122(3):352-361. PubMed ID: 28104300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary CNS lymphoma in HIV infection.
    Brandsma D; Bromberg JEC
    Handb Clin Neurol; 2018; 152():177-186. PubMed ID: 29604975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of the blood-brain barrier in primary central nervous system lymphoma.
    Jahnke K; Doolittle ND; Muldoon LL; Neuwelt EA
    Neurosurg Focus; 2006 Nov; 21(5):E11. PubMed ID: 17134113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
    Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
    Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in primary CNS lymphoma.
    Hoang-Xuan K; Camilleri-Broët S; Soussain C
    Curr Opin Oncol; 2004 Nov; 16(6):601-6. PubMed ID: 15627024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for central nervous system lymphomas in immunocompetent patients.
    Jahnke K; Thiel E
    Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.